4D Molecular Therapeutics Inc (FDMT)
23.97
-0.67
(-2.72%)
USD |
NASDAQ |
May 31, 16:00
24.00
+0.03
(+0.13%)
After-Hours: 20:00
4D Molecular Therapeutics Cash from Financing (Quarterly): 318.83M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 318.83M |
| December 31, 2023 | 4.762M |
| September 30, 2023 | 10.56M |
| June 30, 2023 | 130.52M |
| March 31, 2023 | 10.99M |
| December 31, 2022 | 2.046M |
| September 30, 2022 | 0.46M |
| June 30, 2022 | -0.05M |
| March 31, 2022 | 0.629M |
| Date | Value |
|---|---|
| December 31, 2021 | 116.14M |
| September 30, 2021 | 1.977M |
| June 30, 2021 | 0.82M |
| March 31, 2021 | -0.847M |
| December 31, 2020 | 205.98M |
| September 30, 2020 | 0.90M |
| June 30, 2020 | 72.49M |
| March 31, 2020 | -0.389M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.847M
Minimum
Mar 2021
318.83M
Maximum
Mar 2024
51.52M
Average
2.046M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 23.57M |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Palatin Technologies Inc | 9.136M |
| iBio Inc | 5.025M |
| Theriva Biologics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -29.09M |
| Cash from Investing (Quarterly) | -263.26M |
| Free Cash Flow | -79.44M |
| Free Cash Flow Per Share (Quarterly) | -0.6048 |
| Free Cash Flow to Equity (Quarterly) | -29.80M |
| Free Cash Flow Yield | -7.68% |